Dr. David Ruau joins Sensyne Health from Bayer Pharmaceuticals Oxford, U.K. 22 July 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the ethical AI company, today announces the appointment…
Read More
Oxford, UK – July 20, 2021 – Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today…
Etcembly establishes new lab & office space at TOSP Immune-focused machine learning firm joins leading AI cohort on Park Oxford, UK, July 8 2021 – Etcembly Ltd, a machine learning…
Nature Biotechnology publishes ATDBio & University of Oxford single-cell sequencing research Better understanding of disease possible with accurate full length identification of all messenger RNA in a cell Oxford, UK,…
Oxford, United Kingdom, June 29, 2021: Orbit Discovery Ltd (“Orbit”), a biopharmaceutical company focused on discovering candidate peptide therapeutics using high throughput microfluidic platforms, has announced the appointment of Dr Neil…
Innovative herbicide discovery firm MoA Technology moves to TOSP Third occupier for Bellhouse Building at The Oxford Science Park Oxford, UK, June 28 2021 – MoA Technology, which is focused…
ATDBio establishes molecular diagnostics lab to support customer research Leading nucleic acid maker evolves activity & builds on pandemic experience Oxford, UK, June 21 2021 – ATDBio, a leading…
Deep learning platform evaluates drug activity in patient tumour microenvironments with single cell resolution First AI platform clinically validated to improve treatment outcomes in prospective study Exscientia, a clinical stage…
We are delighted to announce the winners of the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London. The Awards, which are in their 12th year, shine…
Cytox welcomes FDA’s approval of Biogen’s Aduhelm (aducanumab) to treat Alzheimer’s disease Cytox genoSCORE-LAB test can identify patients most at risk of cognitive decline, and potentially most likely to benefit…
Dr. Asmus brings two decades of experience leading global clinical and translational research programs for both retinal and rare diseases. OXFORD, UK, 7 June 2021 – Oxular Limited (“Oxular”), a…
MoA Technology has moved to the Bellhouse Building, a prestigious new facility recently opened at The Oxford Science Park. The first of more than 100 Oxford Sciences Innovation companies focused…
Upfront and potential milestones of over $1.2bn in addition to tiered royalties Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration…
Oxford, UK, May 10 2021 – Magdalen College Oxford, owner of The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies, has announced1 that…
Exscientia, a clinical-stage Artificial Intelligence (AI)-driven pharmatech company, today announced that it has won the Queen’s Award for Enterprise in Innovation, recognising its pioneering work in the field of AI-driven…